Biodesix Achieves First-Ever Adjusted EBITDA Positivity in Q4 2025, Exceeds Revenue Guidance, and Provides Strong 2026 Outlook

summarizeSummary

Biodesix announced Q4 and FY 2025 financial results, reporting its first-ever Adjusted EBITDA positive quarter, exceeding revenue guidance, and providing an optimistic 2026 outlook with continued growth and path to profitability.

check_boxKey Events

• Achieved First-Ever Adjusted EBITDA Positivity

  Biodesix reported Adjusted EBITDA of $0.5 million in Q4 2025, marking the company's first quarter of positive Adjusted EBITDA, a 113% improvement from Q4 2024.

• Exceeded Q4 and FY2025 Revenue Guidance

  Total revenue reached $28.8 million in Q4 2025 (41% YoY growth) and $88.5 million for FY2025 (24% YoY growth), surpassing the high end of the company's raised guidance of $84-86 million for the full year.

• Strong Gross Margin Expansion

  Gross margin expanded to 83% in Q4 2025 (up 400bps YoY) and 81% for FY2025 (up 300bps YoY), driven by diagnostic testing growth and workflow optimization.

• Provided Positive FY2026 Revenue Guidance

  The company anticipates total revenue between $106-112 million for 2026, with the mid-point representing 23% growth over 2025, and expects continued improvement towards sustained Adjusted EBITDA positivity.

auto_awesomeAnalysis

Biodesix reported strong fourth-quarter and full-year 2025 results, significantly exceeding its own revenue guidance and achieving a critical milestone of positive Adjusted EBITDA for the first time. This operational turnaround, coupled with expanding gross margins and a robust 2026 revenue outlook, indicates improved financial health and execution. The subsequent capital raise via an ATM program and the extension of its senior secured term loan further strengthen the balance sheet, providing increased financial flexibility and runway for continued growth. This performance suggests the company is successfully scaling its lung-focused commercial strategy and improving its revenue cycle management.